Skip to content

Phase II Cohort of Spinal Stereotactic Radiotherapy in Patients Using a MR LINAC

Phase II Cohort of Spinal Stereotactic Radiotherapy in Patients Using a MR LINAC

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05709782
Enrollment
40
Registered
2023-02-02
Start date
2023-05-09
Completion date
2029-01-13
Last updated
2026-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Spinal Disease

Brief summary

To learn whether giving spinal stereotactic radiosurgery (SRSS) that uses a more advanced imaging scan method called Magnetic Resonance imaging with a Linear Accelerator (MR-LINAC) during treatment will lead to improved responses to treatment and better quality of life. SRSS is radiation therapy given to the area around your spine.

Detailed description

Primary objective: • To determine the 6-month local control (LC) of the target site of treatment. Secondary Objectives: * To determine the 6-month change in epidural tumor volume (by volumetric measurements where applicable) * To determine the 1-year local control of the target site

Interventions

scan

DEVICEMagnetic Resonance imaging

scan

RADIATIONMR-LINAC

scan

Sponsors

M.D. Anderson Cancer Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Age ≥ 18 years old 2. Radiographically documented disease of the spine within 4 weeks of registration (candidates with or without epidural disease allowed) 3. Candidate for spine SRS/SBRT as determined by treating Radiation Oncologist or Multidisciplinary Spine Conference review 4. Maximum of 3 contiguous vertebral levels involved with metastasis in the spine to be irradiated allowed 5. Diagnosis of cancer documented 6. Motor strength ≥ 4 out of 5 in the extremity affected by the level of spinal disease planned for radiation 7. Karnofsky Performance score (KPS) ≥ 40 or ECOG score ≤ 3

Exclusion criteria

1. Patients with highly radiosensitive histologies likely to respond to conventional radiation therapy alone (ie lymphoma, multiple myeloma, etc) 2. Patients who are unable to undergo MRI of the spine with contrast 3. Patients who are pregnant

Design outcomes

Primary

MeasureTime frameDescription
M. D. Anderson Symptom Inventory - Spine Tumor (MDASI-SP) questionnairesthrough study completion; an average of 1 yearM. D. Anderson Symptom Inventory - Spine Tumor (MDASI-SP) 0 (symptom has not been present) to 10 (the symptom was as bad as you can imagine it could be) for each item.

Countries

United States

Contacts

CONTACTDebra N. Yeboa, MD
dnyeboa@mdanderson.org(713) 563-2415
PRINCIPAL_INVESTIGATORDebra N. Yeboa, MD

M.D. Anderson Cancer Center

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 22, 2026